TriangleCilta-cel (NCT07149857)
Cilta-cel trial for Multiple Myeloma (NCT07149857). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged eighteen to eighty with newly diagnosed multiple myeloma who cannot have or decline high-dose chemotherapy and stem-cell transplant. Induction treatment must produce at least a partial response.
The idea: collect and modify the patient's T cells to target BCMA on myeloma cells. After further induction treatment, patients receive cyclophosphamide alone or with fludarabine, then a ciltacabtagene autoleucel infusion. Researchers assess safety and deep remissions lasting at least twelve months. Some frail patients are excluded.
This phase 2 study plans 60 patients. Janssen sponsors four recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.